The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx

Journal of Nuclear Medicine

Volumn 46, Issue 3, 2005, Pages 405-410

  Yen, Tzu Chen ^a,c   Chang, Joseph Tung Chieh ^a   Ng, Shu Hang ^a   Chang, Yu Chen ^a   Chan, Sheng Chieh ^a   Lin, Kun Ju ^a   Lin, Wuu Jyh ^b   Fu, Ying Kai ^b   Lin, Chen Yu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

18F FDG; M0; Nasopharyngeal carcinoma; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; NASOPHARYNX CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; WHOLE BODY SCINTISCANNING; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; NASOPHARYNX TUMOR; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SINGLE BLIND PROCEDURE; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; VALIDATION STUDY; WHOLE BODY COUNTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; WHOLE-BODY COUNTING;

EID: 17844382717     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet. 1997;350:1087-1091.
2. Chang JT, See LC, Tang SG, Lee SP, Wang CC, Hong JH. The role of brachytherapy in early stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1996;36:1019-1024.
3. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12-22.
4. Oh JL, Vokes EE, Kies MS, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003;14:564-569.
5. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer. 1996;77:2423-2431.
6. Sham JST, Cheung YK, Chan FL, Choy D. Nasopharyngeal carcinoma: pattern of skeletal metastases. Br J Radiol. 1990;63:202-205.
7. King WWK, Ku PKM, Mok CO, Teo PML. Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: a twelve-year experience. Head Neck. 2000;22:215-222.
8. Lee AWM, Law SCK, Foo W, et al. Retrospective analysis of patients with nasopharyngeal carcinoma treatment during 1976-1985: survival after local recurrence. Int J Radiat Oncol Biol Phys. 1993;26:773-782.
9. Vikram B, Mishra UB, Strong EW, Manolatos S. Patterns of failure in carcinoma of the nasopharynx: failure at distant sites. Head Neck Surg. 1986;8:276-279.
10. Lee AWM. Complication. In: Van Hasselt CA, Gibb AG, eds. Nasopharyngeal Carcinoma. Hong Kong: The Chinese University Press; 1991:221-234.
11. Lee AWM, Law SCK, Ng SH, et al. Retrospective analysis of nasopharyngeal carcinoma treated during 1976-1985: late complications following megavoltage irradiation. Br J Radiol. 1992;65:918-928.
12. Ng SH, Chang TC, Ko SF, et al. Nasopharyngeal carcinoma: MRI and CT assessment. Neuroradiology. 1997;39:741-746.
13. Ng SH, Chang TC, Ko SF, Wan YL, Tang LM, Chen WC. MRI in recurrent nasopharyngeal carcinoma. Neuroradiology. 1999;41:855-862.
14. Ng SH, Wan YL, Ko SF, Chang JT. MRI of nasopharyngeal carcinoma with emphasis on relationship to radiotherapy. J Magn Reson Imaging. 1998;8:327-336.
15. Kao CH, ChangLai SP, Chieng PU, Yen RF, Yen TC. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol. 1998;16:3550-3555.
16. Kao CH, Hsieh JF, Tsai SC, et al. Comparison of 18-fluoro-2-deoxyglucose positron emission tomography and computed tomography in detection of cervical lymph node metastases of nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2000;109:1130-1134.
17. Smith RJ, Karp JS, Muehllehner G, et al. Single transmission scans performed post-injection for quantitative whole body PET imaging. IEEE Trans Nucl Sci. 1997;44:1329-1335.
18. Meikle SR, Hutton BF, Bailey DL, Hooper PK, Fulham MJ. Accelerated EM reconstruction in total-body PET: potential for improving tumor detectability. Phys Med Biol. 1994;39:689-1704.
19. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro- D-glucose PET and MR imaging diagnoses. Radiology. 1996;200:135-141.
20. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 2nd-5th eds. Philadelphia, PA: Lippincott-Raven; 1983, 1988, 1992, and 1997.
21. Fandi A, Bachouchi M, Azli N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol. 2000;18:1324-1330.
22. Leung S, Cheung H, Teo P, Lam WW. Staging computed tomography of the thorax for nasopharyngeal carcinoma. Head Neck. 2000;22:369-372.
23. Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology. 2002; 222:773-781.
24. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole body MRI for tumor staging in oncology. JAMA. 2003;290:3199-3206.
25. Kumar MB, Lu JJ, Loh KS, et al. Tailoring distant metastatic imaging for patients with clinically localized undifferentiated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2004;58:688-693.